Abstract
Pretreatment of B-cell lymphoma patients with immunostimulatory gene therapy using armed oncolytic viruses may prime tumor lesions for subsequent chimeric antigen receptor (CAR) T-cell therapy, thereby enhancing CAR T-cell functionality and possibly increasing response rates in patients. LOAd703 (delolimogene mupadenorepvec) is an oncolytic adenovirus (serotype 5/35) that encodes for the transgenes CD40L and 4-1BBL, which activate both antigen-presenting cells and T cells. Many adenoviruses failed to demonstrate efficacy in B-cell malignancies, but LOAd703 infect cells via CD46, which enables B cell infection. Herein, we investigated the therapeutic potential of LOAd703 in human B-cell lymphoma models, alone or in combination with CAR T-cell therapy. LOAd703 could infect and replicate in B-cell lymphoma cell lines (BC-3, Karpas422, Daudi, DG-75, U-698) and induced an overall enhanced immunogenic profile with upregulation of co-stimulatory molecules CD80, CD86, CD70, MHC molecules, death receptor Fas and adhesion molecule ICAM-1. Further, CAR T-cell functionality was boosted by stimulation with lymphoma cells infected with LOAd703. This was demonstrated by an augmented release of IFN-γ and granzyme B, increased expression of the degranulation marker CD107a, fewer PD-1 + TIM-3+ CAR T cells in vitro and enhanced lymphoma cell killing both in in vitro and in vivo xenograft models. In addition, LOAd703-infected lymphoma cells upregulated the secretion of several chemokines (CXCL10, CCL17, CCL22, CCL3, CCL4) essential for immune cell homing, leading to enhanced CAR T-cell migration. In conclusion, immunostimulatory LOAd703 therapy is an intriguing approach to induce anti-lymphoma immune responses and to improve CAR T-cell therapy in B-cell lymphoma.
Highlights
B-cell lymphoma is among the most prevalent hematologic malignancies and is a heterogeneous disease with many subtypes based on tumor cell characteristics and pathogenesis [1]
Chimeric antigen receptor (CAR) T-cell therapy targeting C D19+ B cells has recently been approved for treatment of diffuse large B-cell lymphoma after demonstrating improved outcomes in relapsed/refractory
B‐cell lymphoma cell lines are both targets for CAR T‐cell and LOAd703 therapy
Summary
B-cell lymphoma is among the most prevalent hematologic malignancies and is a heterogeneous disease with many subtypes based on tumor cell characteristics and pathogenesis [1]. Chimeric antigen receptor (CAR) T-cell therapy targeting C D19+ B cells has recently been approved for treatment of diffuse large B-cell lymphoma after demonstrating improved outcomes in relapsed/refractory. Initial response rates in lymphoma are considerably lower than previously noted in leukemia [4, 5]. This is likely due to physical barriers and immunosuppression in the solid lymphoma lesions [6]. Novel treatment approaches intending to modulate the tumor microenvironment (TME), such as immunostimulatory gene therapy using oncolytic viruses, are needed to further improve response rates and prolong survival
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.